Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT ID: NCT05127954

Last Updated: 2025-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

PHASE3

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-14

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants.

Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States.

Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ubrogepant Dose A (12 to 17 Years Old)

Participants will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, at least 2 hours after initial dose for headache of any intensity.

Group Type EXPERIMENTAL

Ubrogepant

Intervention Type DRUG

Oral Tablet

Ubrogepant Dose B (6 to 11 Years Old)

Participants will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, at least 2 hours after initial dose for headache of any intensity.

Group Type EXPERIMENTAL

Ubrogepant

Intervention Type DRUG

Oral Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ubrogepant

Oral Tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ubrelvy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completers of the lead-in Study 3110-305-002 (in the main study or PK cohort) or those who screen failed due to being placebo responders.
* Demonstrated an acceptable degree of compliance with study procedures in the lead-in study and who, in the investigator's clinical judgment, did not experience an AE that may indicate an unacceptable safety risk for this study.

Exclusion Criteria

* Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that is on the list of prohibited concomitant medications that cannot be discontinued or switched to an allowable, alternative medication at Visit 1.
* An ECG with clinically significant abnormalities at Visit 1 as determined by the investigator.
* Clinically significant abnormalities in physical examination at Visit 1, as determined by the investigator.
* Significant risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; participants should be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS), or report suicidal behavior at Visit 1
* Any medical or other reason (eg, unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study) that, in the investigator's opinion, might indicate that the participant is unsuitable for the study.
Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rehabilitation & Neurological Services /ID# 240054

Huntsville, Alabama, United States

Site Status

The Center for Clinical Trials - Saraland /ID# 239448

Saraland, Alabama, United States

Site Status

Preferred Research Partners /ID# 238979

Little Rock, Arkansas, United States

Site Status

Advanced Research Center /ID# 238967

Anaheim, California, United States

Site Status

Neuro Pain Medical Center /ID# 239135

Fresno, California, United States

Site Status

Alliance for Research Alliance for Wellness /ID# 233497

Long Beach, California, United States

Site Status

Children's Hospital Los Angeles /ID# 239446

Los Angeles, California, United States

Site Status

Excell Research, Inc /ID# 233495

Oceanside, California, United States

Site Status

Paradigm Clinical Research - San Diego /ID# 269611

San Diego, California, United States

Site Status

Lumos Clinical Research Center /ID# 239018

San Jose, California, United States

Site Status

Pacific Clinical Research Management Group /ID# 238503

Upland, California, United States

Site Status

Sunwise Clinical Research /ID# 238458

Walnut Creek, California, United States

Site Status

Children's Hospital Colorado - Aurora /ID# 239838

Aurora, Colorado, United States

Site Status

IMMUNOe Research Centers /ID# 240846

Centennial, Colorado, United States

Site Status

MCB Clinical Research Centers /ID# 240999

Colorado Springs, Colorado, United States

Site Status

New England Institute for Clinical Research /ID# 239019

Stamford, Connecticut, United States

Site Status

Emerson Clinical Research Inst /ID# 238455

Washington D.C., District of Columbia, United States

Site Status

Encore Medical Research of Boynton Beach LLC /ID# 248720

Boynton Beach, Florida, United States

Site Status

Gulf Coast Clinical Research Center /ID# 233335

Fort Myers, Florida, United States

Site Status

Sarkis Clinical Trials /ID# 233493

Gainesville, Florida, United States

Site Status

Northwest Florida Clinical Research Group, LLC /ID# 244396

Gulf Breeze, Florida, United States

Site Status

A.G.A Clinical Trials /ID# 238409

Hialeah, Florida, United States

Site Status

Encore Medical Research /ID# 247463

Hollywood, Florida, United States

Site Status

Advanced Research Institute of Miami /ID# 240712

Homestead, Florida, United States

Site Status

Auzmer Research /ID# 241514

Lakeland, Florida, United States

Site Status

Columbus Clinical Services, Llc /Id# 238968

Miami, Florida, United States

Site Status

My Preferred Research LLC /ID# 239020

Miami, Florida, United States

Site Status

Neurology & Pain Medicine /ID# 241860

Miami, Florida, United States

Site Status

Medical Research Group of Central Florida /ID# 240711

Orange City, Florida, United States

Site Status

Clinical Associates of Orlando, LLC /ID# 272623

Orlando, Florida, United States

Site Status

Suncoast Clinical Research - Palm Harbor /ID# 233535

Palm Harbor, Florida, United States

Site Status

Asclepes Research Centers - Spring Hill /ID# 231872

Spring Hill, Florida, United States

Site Status

University of South Florida- Neuroscience Institute /ID# 233420

Tampa, Florida, United States

Site Status

Encore Medical Research - Weston /ID# 248335

Weston, Florida, United States

Site Status

Pediatric Neurology and Epilepsy Specialists /ID# 233336

Winter Park, Florida, United States

Site Status

Global Research Associates /ID# 243504

Atlanta, Georgia, United States

Site Status

Rare Disease Research, LLC /ID# 238833

Atlanta, Georgia, United States

Site Status

Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 238852

Atlanta, Georgia, United States

Site Status

Coastal Georgia Child Neurology /ID# 240845

Brunswick, Georgia, United States

Site Status

CenExcel iResearch LLC /ID# 239832

Decatur, Georgia, United States

Site Status

Velocity Clinical Research - Savannah /ID# 231873

Savannah, Georgia, United States

Site Status

Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 238454

Stockbridge, Georgia, United States

Site Status

Velocity Clinical Research - Boise /ID# 238978

Meridian, Idaho, United States

Site Status

Chicago Headache Center & Research Institute /ID# 254071

Chicago, Illinois, United States

Site Status

Accellacare - McFarland Clinic /ID# 238490

Ames, Iowa, United States

Site Status

College Park Family Care Center Overland Park /ID# 240707

Overland Park, Kansas, United States

Site Status

Clinical Associates Midwest, LLC /ID# 274356

Overland Park, Kansas, United States

Site Status

Psychiatric Associates /ID# 240710

Overland Park, Kansas, United States

Site Status

Alliance for Multispecialty Research (AMR) - Wichita West /ID# 239829

Wichita, Kansas, United States

Site Status

University of Kentucky Chandler Medical Center /ID# 233428

Lexington, Kentucky, United States

Site Status

Pharmasite Research, Inc. /ID# 233414

Baltimore, Maryland, United States

Site Status

Minneapolis Clinic of Neurology - Burnsville /ID# 238828

Burnsville, Minnesota, United States

Site Status

MediSync Clinical Research Hattiesburg Clinic /ID# 239837

Petal, Mississippi, United States

Site Status

Proven Endpoints LLC /ID# 240974

Ridgeland, Mississippi, United States

Site Status

Sharlin Health Neuroscience Research Center /ID# 238969

Ozark, Missouri, United States

Site Status

Cognitive Clinical Trials (CCT) - Papillion /ID# 239835

Papillion, Nebraska, United States

Site Status

Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 239441

Nashua, New Hampshire, United States

Site Status

Hunterdon Neurology /ID# 248222

Annandale, New Jersey, United States

Site Status

Goryeb Children's Hospital /ID# 239425

Morristown, New Jersey, United States

Site Status

CVS HealthHUB - Runnemede /ID# 240057

Runnemede, New Jersey, United States

Site Status

Dent Neurologic Institute - Amherst /ID# 238415

Amherst, New York, United States

Site Status

Bioscience Research /ID# 239442

Mount Kisco, New York, United States

Site Status

Modern Migraine MD /ID# 263140

New York, New York, United States

Site Status

North Suffolk Neurology /ID# 238457

Port Jefferson Station, New York, United States

Site Status

SUNY Upstate Medical University /ID# 241140

Syracuse, New York, United States

Site Status

CVS HealthHUB - Charlotte /ID# 240842

Charlotte, North Carolina, United States

Site Status

OnSite Clinical Solutions, LLC - Hickory /ID# 238946

Hickory, North Carolina, United States

Site Status

Patient Priority Clinical Sites, LLC /ID# 240051

Cincinnati, Ohio, United States

Site Status

University of Cincinnati /ID# 238461

Cincinnati, Ohio, United States

Site Status

Cincinnati Childrens Hospital Medical Center /ID# 247491

Cincinnati, Ohio, United States

Site Status

Headache Center of Hope /ID# 244819

Cincinnati, Ohio, United States

Site Status

Centricity Research Columbus /ID# 238832

Columbus, Ohio, United States

Site Status

CincyScience /ID# 233334

West Chester, Ohio, United States

Site Status

IPS Research Company /ID# 231876

Oklahoma City, Oklahoma, United States

Site Status

Providence Brain and Spine Institute /ID# 240050

Portland, Oregon, United States

Site Status

Children's Hospital of Philadelphia - Main /ID# 241138

Philadelphia, Pennsylvania, United States

Site Status

Frontier Clinical Research, LLC - Scottdale /ID# 239017

Scottdale, Pennsylvania, United States

Site Status

Frontier Clinical Research - Smithfield /ID# 238502

Smithfield, Pennsylvania, United States

Site Status

Coastal Pediatric Research /ID# 240708

Charleston, South Carolina, United States

Site Status

Tribe Clinical Research LLC /ID# 239143

Greenville, South Carolina, United States

Site Status

Duplicate_Premier Neurology, P.C. /ID# 233419

Greer, South Carolina, United States

Site Status

Access Clinical Trials, Inc. /ID# 238414

Nashville, Tennessee, United States

Site Status

UT Health Austin at Dell Children's Neurology Clinic /ID# 246570

Austin, Texas, United States

Site Status

BioBehavioral Research of Austin /ID# 233427

Austin, Texas, United States

Site Status

Velocity Clinical Research, Austin /ID# 233406

Austin, Texas, United States

Site Status

Tekton Research - Beaumont /ID# 238407

Beaumont, Texas, United States

Site Status

Relaro Medical Trials /ID# 241141

Dallas, Texas, United States

Site Status

Cedar Health Research /ID# 233403

Dallas, Texas, United States

Site Status

3A Research - East El Paso /ID# 241665

El Paso, Texas, United States

Site Status

Earle Research /ID# 238940

Friendswood, Texas, United States

Site Status

DM Clinical Research /ID# 238361

Houston, Texas, United States

Site Status

Houston Clinical Research Associates /ID# 246522

Houston, Texas, United States

Site Status

Sante Clinical Research /ID# 248333

Kerrville, Texas, United States

Site Status

FMC Science /ID# 240475

Lampasas, Texas, United States

Site Status

Livingspring Family Medical Center /ID# 252194

Mansfield, Texas, United States

Site Status

AIM Trials /ID# 233425

Plano, Texas, United States

Site Status

Road Runner Research /ID# 238360

San Antonio, Texas, United States

Site Status

Family Psychiatry of The Woodlands /ID# 238980

The Woodlands, Texas, United States

Site Status

ClinPoint Trials /ID# 238406

Waxahachie, Texas, United States

Site Status

Pantheon Clinical Research /ID# 251475

Bountiful, Utah, United States

Site Status

Highland Clinical Research /ID# 240053

Salt Lake City, Utah, United States

Site Status

University of Utah Health Hospital /ID# 239021

Salt Lake City, Utah, United States

Site Status

Neuropsychiatric Associates LLC/DBA Woodstock Research Center /ID# 240055

Woodstock, Vermont, United States

Site Status

Office of Maria Ona /ID# 239833

Franklin, Virginia, United States

Site Status

Children's Hospital of The King's Daughters - Children's Medical Tower /ID# 239142

Norfolk, Virginia, United States

Site Status

National Clinical Research /ID# 238419

Richmond, Virginia, United States

Site Status

Core Clinical Research /ID# 233421

Everett, Washington, United States

Site Status

Frontier Clinical Research - Kingwood /ID# 238459

Kingwood, West Virginia, United States

Site Status

Mind+ Neurology /ID# 275538

Mequon, Wisconsin, United States

Site Status

Clinical Research Investigator Group, LLC /ID# 267458

Bayamón, , Puerto Rico

Site Status

Puerto Rico Health Institute /ID# 250560

Dorado, , Puerto Rico

Site Status

GCM Medical Group PSC /ID# 250561

San Juan, , Puerto Rico

Site Status

Caribbean Medical Research Center /ID# 265292

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Related Links

Access external resources that provide additional context or updates about the study.

https://www.rxabbvie.com/

This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3110-306-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.